Evelo Biosciences (NASDAQ: EVLO) is one of 548 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Evelo Biosciences to related businesses based on the strength of its valuation, profitability, risk, institutional ownership, earnings, analyst recommendations and dividends.
This table compares Evelo Biosciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Evelo Biosciences Competitors||-1,760.46%||-120.17%||-28.09%|
This is a summary of current recommendations and price targets for Evelo Biosciences and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Evelo Biosciences Competitors||4546||13020||27670||994||2.54|
Evelo Biosciences presently has a consensus target price of $22.75, indicating a potential upside of 174.10%. As a group, “Pharmaceutical preparations” companies have a potential upside of 58.43%. Given Evelo Biosciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Evelo Biosciences is more favorable than its rivals.
Institutional & Insider Ownership
85.1% of Evelo Biosciences shares are held by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.9% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Evelo Biosciences and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Evelo Biosciences||N/A||-$56.94 million||-2.99|
|Evelo Biosciences Competitors||$2.15 billion||$228.73 million||-3.52|
Evelo Biosciences’ rivals have higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Evelo Biosciences beats its rivals on 7 of the 12 factors compared.
Evelo Biosciences Company Profile
Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. Evelo Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.